We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

93 hedge funds and large institutions have $272M invested in Merrimack Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 27 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

241% more call options, than puts

Call options by funds: $2.5M | Put options by funds: $731K

36% more capital invested

Capital invested by funds: $200M → $272M (+$71.9M)

7% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 27

2% less funds holding

Funds holding: 95 → 93 (-2)

10% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 20

Holders
93
Holders Change
-2
Holders Change %
-2.11%
% of All Funds
2.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
29
Reduced
27
Closed
20
Calls
$2.5M
Puts
$731K
Net Calls
+$1.76M
Net Calls Change
+$1.79M

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$4M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$3.97M
3
Morgan Stanley
Morgan Stanley
New York
+$3.45M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.61M
5
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
California
+$2.16M

Top Sellers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
-$8.45M
2
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$5.34M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$4.91M
4
O
OppenheimerFunds
New York
-$2.83M
5
MF
Magnetar Financial
Illinois
-$1.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
PI
26
Putnam Investments
Massachusetts
$1.62M +$9.51K +328 +0.9%
William Blair & Company
27
William Blair & Company
Illinois
$1.49M +$1.02M +35,347 New
BIM
28
BlackRock Investment Management
Delaware
$1.43M -$17.6K -607 -2%
Charles Schwab
29
Charles Schwab
California
$1.28M +$74.5K +2,570 +9%
CT
30
Cambridge Trust
Massachusetts
$1.23M -$14.8K -509 -2%
Millennium Management
31
Millennium Management
New York
$1.04M +$21.2K +731 +3%
U
32
UBS
Switzerland
$938K +$92.1K +3,178 +17%
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$934K +$7.74K +267 +1%
Goldman Sachs
34
Goldman Sachs
New York
$920K +$38K +1,310 +6%
TA
35
Teachers Advisors
New York
$848K +$37.1K +1,281 +7%
WMSA
36
Weiss Multi-Strategy Advisers
New York
$693K +$184K +6,355 +63%
Brown Advisory
37
Brown Advisory
Maryland
$619K – – –
AllianceBernstein
38
AllianceBernstein
Tennessee
$577K -$198K -6,826 -33%
GBA
39
Garrison Bradford & Associates
New York
$522K – – –
Swiss National Bank
40
Swiss National Bank
Switzerland
$493K – – –
VOYA Investment Management
41
VOYA Investment Management
Georgia
$467K +$81.3K +2,804 +34%
SIP
42
Stoneridge Investment Partners
Pennsylvania
$445K – – –
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$428K -$12.2K -420 -4%
JEW
44
Jamison Eaton & Wood
New Jersey
$415K +$118K +4,067 +70%
KCM
45
Knoll Capital Management
Florida
$400K +$276K +9,533 New
NFA
46
Nationwide Fund Advisors
Ohio
$399K -$7.07K -244 -3%
MLICM
47
Metropolitan Life Insurance Company (MetLife)
New York
$396K – – –
IAM
48
Integre Asset Management
New York
$368K +$255K +8,782 New
SIM
49
SSI Investment Management
California
$365K +$252K +8,696 New
AIG
50
American International Group
New York
$348K +$11.9K +409 +5%
1
2
3 4 5

MACK Hedge Fund Activity: Q4 2013 in Review

93 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2013, worth a combined $272M — up 36% from $200M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of MACK and 18 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 29 added.

The largest buyer was Jennison Associates, adding an estimated $4M. The largest seller was Credit Suisse, cutting an estimated $8.45M.

  • 93 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2013, down from 95 in Q3 2013.
  • Funds reported $272M of Merrimack Pharmaceuticals, Inc. stock for Q4 2013, up 36% quarter-over-quarter.
  • 18 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2013 and 20 closed out, a net change of -2 holders.
  • The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2013 was Jennison Associates, an estimated $4M added.
  • The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2013 was Credit Suisse, an estimated $8.45M sold.

Based on aggregated 13F filings for Q4 2013.